Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Uterine Cervical Neoplasms*/pathology ; Uterine Cervical Neoplasms*/surgery ; Uterine Cervical Neoplasms*/therapy ; Chemoradiotherapy* ; Radiotherapy, Adjuvant*; Humans ; Adult ; Retrospective Studies ; Neoplasm Staging ; Hysterectomy ; Lymph Node Excision ; Radiation Dosage ; Treatment Outcome ; Survival Rate ; Middle Aged ; Aged

Purpose: For patients with early-stage cervical cancer without high-risk factors, there is no consensus regarding the optimal postoperative treatment regimen and whether postoperative concurrent radiochemotherapy (CCRT) is superior to radiotherapy (RT) alone.
Patients and Methods: The medical records of patients with stage I-IIA cervical cancer, who underwent radical surgery and postoperative RT or CCRT between June 2012 and December 2017, were retrospectively reviewed. Patients with any high-risk factors, including positive pelvic lymph node(s), positive resection margin(s), and parametrial invasion, were excluded. Patients with large tumors (≥ 4 cm), deep stromal invasion (≥ 1/2), and lymphovascular space involvement were categorized as the intermediate-risk group. Patients without intermediate-risk factors were categorized as the low-risk group.
Results: A total of 403 patients were enrolled and divided into 2 groups according to postoperative treatment: RT alone (n = 105); and CCRT (n = 298). For risk stratification, patients were also divided into 2 groups: intermediate-risk (n = 350); and low-risk (n = 53). The median follow-up was 51.7 months. Patients in the intermediate-risk group and those with multiple intermediate-risk factors were more likely to undergo CCRT. For patients who underwent RT alone or CCRT in the intermediate-risk group, 5-year overall survival (OS) rates were 93.4% and 93.8% (p = 0.741), and 5-year disease-free survival (DFS) rates were 90.6% and 91.4%, respectively (p = 0.733). Similarly, for patients who underwent RT alone or CCRT in the low-risk group, the 5-year OS rates were 100.0% and 93.5% (p = 0.241), and 5-year DFS rates were 94.4% and 93.5%, respectively (p = 0.736). Adjuvant CCRT or RT were not independent risk factors for either OS or DFS. Patients who underwent CCRT appeared to develop a higher proportion of grade ≥ 3 acute hematological toxicities than those in the RT group (44.0% versus 11.4%, respectively; p < 0.001). There was no significant difference in grade ≥ 3 chronic toxicities of the urogenital and gastrointestinal systems between the CCRT and RT groups.
Conclusion: There was no significant difference in 5-year OS and DFS rates between patients with early-stage cervical cancer without high-risk factors undergoing postoperative CCRT versus RT alone. Patients who underwent CCRT appeared to develop a higher proportion of grade ≥ 3 acute hematological toxicities than those who underwent RT alone.
(© 2024. The Author(s).)

Eur J Surg Oncol. 2009 Feb;35(2):192-6. (PMID: 18490129)
Int J Gynecol Cancer. 2013 Mar;23(3):567-75. (PMID: 23385284)
BMC Cancer. 2015 May 04;15:353. (PMID: 25935645)
Gynecol Oncol. 2009 Dec;115(3):482-7. (PMID: 19783286)
Gynecol Oncol. 1999 May;73(2):177-83. (PMID: 10329031)
Jpn J Clin Oncol. 2017 Jan;47(1):32-38. (PMID: 27677664)
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76. (PMID: 16427212)
BMC Cancer. 2017 Apr 28;17(1):297. (PMID: 28454573)
Gynecol Oncol. 2016 Dec;143(3):539-544. (PMID: 27769525)
Gynecol Oncol. 1989 Apr;33(1):34-9. (PMID: 2703164)
Int J Surg. 2017 Aug;44:1-6. (PMID: 28583891)
J Gynecol Oncol. 2020 May;31(3):e35. (PMID: 31912685)
Radiat Oncol. 2018 Dec 17;13(1):249. (PMID: 30558636)
Gynecol Oncol. 2012 Jan;124(1):63-7. (PMID: 22004904)
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):794-9. (PMID: 20421158)
Asian Pac J Cancer Prev. 2016;17(8):3945-51. (PMID: 27644643)
J Clin Oncol. 2000 Apr;18(8):1606-13. (PMID: 10764420)
Gynecol Oncol. 2005 Jun;97(3):727-32. (PMID: 15943983)
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):429-36. (PMID: 20542643)
Acta Obstet Gynecol Scand. 2014 Jul;93(7):661-8. (PMID: 24666257)

2022-PUMCH-A-103 National High-Level Hospital Clinical Research Funding; 2022YFC2402305 National Key Research and Development Program of China

Keywords: Cervical cancer; Deep stromal invasion; Large tumor size; Lymphovascular space involvement; Postoperative concurrent radiochemotherapy; Radiotherapy

Date Created: 20240430 Date Completed: 20240430 Latest Revision: 20240613

20240614

PMC11061922

10.1186/s12885-024-12284-9

38689248